Henry C. Marsh

5.6k citations

93 papers · 4.5k indexed · 2 hit papers · h-index 37

Impact in

Immunology top 1%
- Complement system in diseases
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Transplantation top 2%

Papers in

Immunology 54
- Complement system in diseases 20
- Immunotherapy and Immune Responses 19
- Immune Cell Function and Interaction 14
- T-cell and B-cell Immunology 10
Hematology 12

Co-authors: Gerald Carson Michael F. Concino H. Yasuda Michael Boyle Myron L. Weisfeldt Douglas T. Fearon Kenneth H. Roux Michelle K. Leppo
Journals: Journal of Biological Chemistry (7 papers)The Journal of Immunology (6 papers)Transplantation (6 papers)Cancer Research (5 papers)Journal of Applied Polymer Science (4 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Henry C. Marsh

92 papers receiving 4.3k citations

Hit Papers

align trajectories log scale

Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination 2019 · 321 citations

Peers

Countries citing papers authored by Henry C. Marsh

Since Specialization

Citations

This map shows the geographic impact of Henry C. Marsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry C. Marsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry C. Marsh more than expected).

Fields of papers citing papers by Henry C. Marsh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry C. Marsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry C. Marsh. The network helps show where Henry C. Marsh may publish in the future.

Co-authors

The 25 scholars most cited alongside Henry C. Marsh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Henry C. Marsh Line = papers co-authored together Henry C. Marsh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity Nature Communications ·Judit Svensson‐Arvelund, SUSRIYATI MAHANAL, 刘金鑫, Doksoo Lee, Mark Aleynick, Linda Hammerich, Ranjan Upadhyay, Michael Yellin, Henry C. Marsh, Jillian Kalman, Suchit Jhunjhunwala, Christine Moussion, Miriam Mérad, Brian D. Brown, Adolfo Garcı́a-Sastre, Joshua Brody	2022	38
2	Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice Cancer Immunology Immunotherapy ·Anna Wasiuk, Putri Intan Pertiwi, E. W. Clarke, Jenifer Widger, Andrea Crocker, Laura Vitale, Henry C. Marsh, Tibor Keler, Li-Zhen He	2021	4
3	A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells The Journal of Immunology ·Takaaki Oba, Toshifumi Hoki, Takayoshi Yamauchi, Tibor Keler, Henry C. Marsh, Xuefang Cao, Fumito Ito	2020	27
4	Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s Nature Communications ·Takaaki Oba, Mark D. Long, Tibor Keler, Henry C. Marsh, Hans Minderman, Scott I. Abrams, Song Liu, Fumito Ito	2020	105
5	Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy Cancer Immunology Immunotherapy ·Laura Vitale, Lawrence J. Thomas, Li-Zhen He, Thomas J. O’Neill, Jenifer Widger, Andrea Crocker, Karuna Sundarapandiyan, James R. Storey, G. A. Yagunova, Gengxin XIE, Chengmin He, 亮吾菊地, Sanne M. Snelder, E. W. Clarke, J. Goldstein, Henry C. Marsh, Tibor Keler	2018	39
6	CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy The Journal of Immunology ·Anna Wasiuk, James Testa, Putri Intan Pertiwi, E. W. Clarke, Laura Vitale, Jenifer Widger, Andrea Crocker, Lawrence J. Thomas, J. Goldstein, Henry C. Marsh, Tibor Keler, Li-Zhen He	2017	40
7	Development of a Novel Antibody–Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1 Molecular Cancer Therapeutics ·Lawrence J. Thomas, Laura Vitale, Thomas J. O’Neill, مهرداد رزاقیان قادیکلایی, Paul K. Wallace, Hans Minderman, 亮吾菊地, G. A. Yagunova, Sanne M. Snelder, James R. Storey, Hyemin Kim, Russell A. Hammond, Jenifer Widger, Karuna Sundarapandiyan, Andrea Crocker, Henry C. Marsh, Tibor Keler	2016	34
8	Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab Journal for ImmunoTherapy of Cancer ·Venky Ramakrishna, Karuna Sundarapandiyan, Biwei Zhao, Max Bylesjö, Henry C. Marsh, Tibor Keler	2015	51
9	Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers Bone Marrow Transplantation ·Niroshana Anandasabapathy, Gaëlle Breton, Arlene Hurley, Marina Caskey, Christine Trumpfheller, Potukuchi Venkata Gurunadha Krishna Sarma, James Pring, Maggi Pack, Noreen Buckley, Irina Matei, David Lyden, 羽田宏, Thomas Hawthorne, Henry C. Marsh, Michael Yellin, D. P. S. Sethi, Tibor Keler, Sarah J. Schlesinger	2015	81
10	Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity OncoImmunology ·Lawrence J. Thomas, Li-Zhen He, Henry C. Marsh, Tibor Keler	2014	23
11	Complement activation is critical for placental ischemia-induced hypertension in the rat Molecular Immunology ·Karakaya, 孔令体, Claire-Helene Verdiere, Ashley J. Bauer, Henry C. Marsh, Jeffrey S. Gilbert, Jean F. Regal	2013	45
12	Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models Journal for ImmunoTherapy of Cancer ·Li-Zhen He, Lawrence J. Thomas, James Testa, Gengxin XIE, E. W. Clarke, Russell A. Hammond, Laura Vitale, Henry C. Marsh, Tibor Keler	2013	3
13	The Partly Folded Back Solution Structure Arrangement of the 30 SCR Domains in Human Complement Receptor Type 1 (CR1) Permits Access to its C3b and C4b Ligands Journal of Molecular Biology ·Patricia B. Furtado, 金根泰, Sunil Rodger, Russell A. Hammond, Henry C. Marsh, Stephen J. Perkins	2007	33
14	Pre‐clinical evaluation of an sLe^x‐glycosylated complement inhibitory protein in a non‐human primate model of reperfused stroke Journal of Medical Primatology ·Andrew F. Ducruet, J Mocco, William J. Mack, Alexander L. Coon, Henry C. Marsh, David J. Pinsky, Zachary L. Hickman, Grace H. Kim, E. Sander Connolly	2007	16
15	Activation of the spinal cord complement cascade might contribute to mechanical allodynia induced by three animal models of spinal sensitization Journal of Pain ·Derek Moore, Evan M. Sloane, Ксения Александровна Дубова, Erin D. Milligan, Fatima Janoub, Henry C. Marsh, Steven F. Maier, Linda R. Watkins	2005	47
16	A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway European Journal of Immunology ·Susanne M. Scesney, Savvas C. Makrides, Michael Gosselin, Pamella J. Ford, Beth Andrews, Edward G. Hayman, Henry C. Marsh	1996	28
17	Design, Synthesis, and Evaluation of A-, C-, and D-Ring Analogs of the Fungal Metabolite K-76 as Potential Complement Inhibitors Journal of Medicinal Chemistry ·Teodoro S. Kaufman, Neilan Amber, Robert D. Sindelar, Susanne M. Scesney, Henry C. Marsh	1995	20
18	THE EFFECT OF SOLUBLE COMPLEMENT RECEPTOR TYPE 1 ON HYPERACUTE REJECTION OF PORCINE XENOGRAFTS Transplantation ·Scott K. Pruitt, Allan D. Kirk, R. Randal Bollinger, Henry C. Marsh, Bradley H. Collins, James L. Levin, James R. Mault, Jeffrey S. Heinle, Sherif Ibrahim, Alfred R. Rudolph, Guanlong Ren, Fred Sanfilippo	1994	199
19	Characterization of monoclonal antibodies specific for the Vβ3 family of the human T cell receptor generated using soluble TCR β-chain Journal of Immunological Methods ·Christian Brecher, Gerald Carson, Olga Balachova, FA Stokes, Rolf Kuestner, Asma Ahmed, E M Wilson, Augustine Y. Lin, Charles W. Rittershaus, Henry C. Marsh, Nancy H. Jones	1993	11
20	Two Distinct Immunogenic Epitopes on the α Chain of Human T Cell Antigen Receptor Hybridoma ·Olga Balachova, Maria Eliza de Paula Monteiro de Castro Casimiro, Charles W. Rittershaus, Ren Ming Wang, Henry C. Marsh, S H Ip	1989	12

About Henry C. Marsh

Henry C. Marsh is a scholar working on Immunology, Hematology, Radiology, Nuclear Medicine and Imaging, Oncology and Transplantation, having authored 93 papers that have together received 4.5k indexed citations. Recurring topics across this work include Complement system in diseases (20 papers), Immunotherapy and Immune Responses (19 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (14 papers), Immune Cell Function and Interaction (14 papers), T-cell and B-cell Immunology (10 papers) and Xenotransplantation and immune response (8 papers). The work is most often cited by research in Immunology (2.3k citations), Transplantation (152 citations), Hematology (512 citations), Nephrology (233 citations) and Neurology (256 citations). Henry C. Marsh has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Gerald Carson, Michael F. Concino, H. Yasuda, Michael Boyle, Myron L. Weisfeldt, Douglas T. Fearon, Kenneth H. Roux, Michelle K. Leppo, Harlan F. Weisman and Tibor Keler. Their work appears in journals such as Journal of Biological Chemistry, The Journal of Immunology, Transplantation, Cancer Research and Journal of Applied Polymer Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact